Considerations in Use of Biosimilars for Gastrointestinal Disorders

Duration

.5 hours

About

In this on demand webcast, Stephen B. Hanauer, MD, AGAF and David T. Rubin, MD, AGAF provide an overview of the current body of knowledge on the safety and efficacy of biosimilar products. Biosimilar pricing is explored, as well as the impact of payor decisions on clinical GI practice. This activity is a collaboration of the AGA Institute and the Crohn's and Colitis Foundation.

This program is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc.

Who Should Take this Course

This activity is intended for gastroenterologists, GI fellows, nurse practitioners, physician assistants and other healthcare professionals who treat GI disorders.

Learning Objectives

At the conclusion of this presentation, learners will:

Appreciate the landscape that has contributed to the emergence of biosimilars in the U.S. IBD market

Gain clarity on the definition of biosimilars and the abbreviated FDA approval pathway

Appreciate the rationale for extrapolation of indications

Know that no biosimilar has received an interchangeable designation

Consider the clinical scenarios in which biosimilars may be utilized safely

CME / Maintenance of Certification (MOC) Information

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AGA Institute designates this enduring activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Successful completion of this CME activity enables the participant to earn up to .5 MOC points in the American Board of Internal Medicine’s (ABIM) MOC program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.